Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer C Cooper

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|May 19, 2025
Precision Medicine in Pediatric Autoimmunity: Leniolisib Treatment of Childhood-Onset Lupus Nephritis Due to Activated PI3K-Delta Syndrome (APDS)Jonathan P Lim, Mansooreh Ahmadian, Hongyu Du, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 24, 2021
Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic PolyangiitisPaul Brogan, Rae S M Yeung, Gavin Cleary, et al.
Pediatric Rheumatology Online Journal|October 24, 2018
Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritisJennifer C Cooper, Kelly Rouster-Stevens, Tracey B Wright, et al.
Frontiers in Immunology|November 15, 2023
Expansion of extrafollicular B and T cell subsets in childhood-onset systemic lupus erythematosusRyan M Baxter, Christine S Wang, Josselyn E Garcia-Perez, et al.
ACR Open Rheumatology|November 26, 2025
Characteristics Associated With EuroLupus Versus Modified National Institutes of Health Cyclophosphamide Regimen Use in Children and Young Adults With Lupus NephritisChristine S Wang, Rebecca E Sadun, Wenru Zhou, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 6, 2023
Renal Response Outcomes of the EuroLupus and National Institutes of Health Cyclophosphamide Dosing Regimens in Childhood-Onset Proliferative Lupus NephritisChristine S Wang, Rebecca E Sadun, Wenru Zhou, et al.
Nature Reviews. Rheumatology|July 2, 2025
CAR T cell therapy for children with rheumatic disease: the time is nowHolly Wobma, Stacy P Ardoin, Challice L Bonifant, et al.
Pediatric Nephrology (Berlin, Germany)|October 17, 2022
Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research AllianceBrian R Stotter, Ellen Cody, Hongjie Gu, et al.
Journal of Clinical Trials|July 22, 2024
Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis-A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil Study)Anna Carmela P Sagcal-Gironella, Angela Merritt, Tomoyuki Mizuno, et al.
RMD Open|October 6, 2025
Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspectiveElena W Y Hsieh, James B Chung, Afsah Amin, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Arthritis & Rheumatology (Hoboken, N.J.)|May 19, 2025
Precision Medicine in Pediatric Autoimmunity: Leniolisib Treatment of Childhood-Onset Lupus Nephritis Due to Activated PI3K-Delta Syndrome (APDS)Jonathan P Lim, Mansooreh Ahmadian, Hongyu Du, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 24, 2021
Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic PolyangiitisPaul Brogan, Rae S M Yeung, Gavin Cleary, et al.
Pediatric Rheumatology Online Journal|October 24, 2018
Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritisJennifer C Cooper, Kelly Rouster-Stevens, Tracey B Wright, et al.
Frontiers in Immunology|November 15, 2023
Expansion of extrafollicular B and T cell subsets in childhood-onset systemic lupus erythematosusRyan M Baxter, Christine S Wang, Josselyn E Garcia-Perez, et al.
ACR Open Rheumatology|November 26, 2025
Characteristics Associated With EuroLupus Versus Modified National Institutes of Health Cyclophosphamide Regimen Use in Children and Young Adults With Lupus NephritisChristine S Wang, Rebecca E Sadun, Wenru Zhou, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 6, 2023
Renal Response Outcomes of the EuroLupus and National Institutes of Health Cyclophosphamide Dosing Regimens in Childhood-Onset Proliferative Lupus NephritisChristine S Wang, Rebecca E Sadun, Wenru Zhou, et al.
Nature Reviews. Rheumatology|July 2, 2025
CAR T cell therapy for children with rheumatic disease: the time is nowHolly Wobma, Stacy P Ardoin, Challice L Bonifant, et al.
Pediatric Nephrology (Berlin, Germany)|October 17, 2022
Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research AllianceBrian R Stotter, Ellen Cody, Hongjie Gu, et al.
Journal of Clinical Trials|July 22, 2024
Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis-A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil Study)Anna Carmela P Sagcal-Gironella, Angela Merritt, Tomoyuki Mizuno, et al.
RMD Open|October 6, 2025
Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspectiveElena W Y Hsieh, James B Chung, Afsah Amin, et al.
Pageof 3